...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pain research & management: the journal of the Canadian Pain Society = journal de la socie?te? canadienne pour le traitement de la douleur >Patient-Controlled Intravenous Analgesia for Advanced Cancer Patients with Pain: A Retrospective Series Study
【24h】

Patient-Controlled Intravenous Analgesia for Advanced Cancer Patients with Pain: A Retrospective Series Study

机译：患者控制静脉镇痛针对晚期癌症患者的痛苦：回顾性系列研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective. To compare the efficacy and side effects of patient-controlled intravenous analgesia (PCIA) with hydromorphone, sufentanil, and oxycodone on the management of advanced cancer patients with pain. Methods. Patients allocated to receive PCIA between January 2015 and December 2016 were chosen for this study. After reviewing medical records, we verified if hydromorphone, sufentanil, or oxycodone for PCIA could equally provide effective pain relief. A numeric rating scale (NRS) of cancer pain was applied before PCIA, at 4 hours after PCIA, and at the discontinuation of PCIA. Secondary, the incidence of clinical side effects attributed to PCIA was observed. Results. A total of 85 medical records were reviewed. PCIA with hydromorphone (n=30), sufentanil (n=34), and oxycodone (n=21) was used for cancer pain management. PCIA successfully improved pain control in 97.6% of the patients. The most common side effects were constipation (11.8%), nausea (8.2%), and sedation (5.9%). Drug addiction, delirium, or respiratory depression associated with PCIA was not reported in this case series study. No significant intergroup difference was observed in NRS at any of the abovementioned time points. There was no significant difference of analgesic effect among the hydromorphone, sufentanil, or oxycodone. Conclusion. PCIA provided timely, safe, and satisfactory analgesia for advanced cancer patients with pain and may be useful for titration of opioids, management of severe breakthrough pain, and conversion to oral analgesia. There was no significant difference of analgesic effect and side effect among the hydromorphone, sufentanil, and oxycodone.
机译：客观的。比较患者控制静脉镇痛（PCIA）与氢磷脂，苏芬太尼和羟考酮对晚期癌症患者疼痛管理的疗效和副作用。方法。为本研究选择了分配给2016年1月和2016年12月之间接受PCIA的患者。在审查病历后，我们验证了PCIA的氢丙酮，苏芬太尼或羟考酮，同样可以提供有效的疼痛缓解。在PCIA后4小时后，在PCIA后4小时，在PCIA停止后，癌症疼痛的数值评定量表（NRS）。中等，观察到归因于PCIA的临床副作用的发病率。结果。共有85条医疗记录进行了审查。用氢质酮（n = 30），Sufentanil（n = 34）和羟考酮（n = 21）用于癌症疼痛管理。 PCIA在97.6％的患者中成功改善了疼痛控制。最常见的副作用是便秘（11.8％）恶心（8.2％）和镇静（5.9％）。在本案例中没有报道与PCIA相关的吸毒成瘾，谵妄或呼吸抑郁症。在任何上述时间点，在NR中没有观察到显着的互动差异。液体白酮，苏芬太尼或羟考酮之间镇痛作用差异无统计学。结论。 PCIA为晚期癌症患者提供及时，安全，令人满意的镇痛，可用于滴定阿片类药物，剧烈突破疼痛的管理，并转化为口腔镇痛。余酮，苏芬太尼和羟考酮之间的镇痛作用和副作用没有显着差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号